Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)15.16
  • Today's Change-0.43 / -2.76%
  • Shares traded1.59m
  • 1 Year change-34.94%
  • Beta1.4852
Data delayed at least 15 minutes, as of Feb 16 2026 04:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.

  • Revenue in HKD (TTM)3.45bn
  • Net income in HKD-1.62bn
  • Incorporated2013
  • Employees1.87k
  • Location
    Zai Lab LtdBuilding B, 899 Halei Road, PudongSHANGHAI 201203ChinaCHN
  • Phone+86 2 161632588
  • Fax+86 2 161632570
  • Websitehttps://www.zailaboratory.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hbm Holdings Ltd904.32m571.07m10.28bn210.0015.964.2517.1911.370.74050.74051.142.780.38566.3232.645,796,901.0024.77-42.8730.77-53.2492.9596.1264.25-292.586.0228.630.1857---57.4347.71-87.81---55.31--
China Traditional Chinese Med Hldg CoLtd17.63bn-299.61m10.32bn15.58k--0.440811.360.5854-0.0595-0.05953.504.650.43261.591.711,052,615.00-0.933.48-1.425.2447.6654.69-2.157.391.519.550.133321.27-8.902.89-95.79-49.14-15.28-48.82
Luye Pharma Group Ltd6.98bn449.06m10.79bn5.12k22.620.6116.741.550.11940.11941.864.420.20832.422.371,354,931.001.911.983.263.1666.8568.379.158.041.242.350.42270.00-1.33-0.9503-11.40-19.50-10.95--
Fujian Haixi Pharmaceuticals Co Ltd-100.00bn-100.00bn10.92bn--------------------------------------------------47.39--15.86------
Guangzhou Innogen Pharmaceutl Grp Co Ltd-100.00bn-100.00bn12.79bn105.00--15.05----------1.84------------------------3.39--0.0769------76.18------
Everest Medicines Ltd963.07m-745.25m13.88bn722.00--2.90--14.41-2.31-2.312.9813.550.168413.973.041,448,222.00-13.03-29.28-14.21-31.6769.92---77.38-1,040.865.43--0.1577--461.16---23.32--16.96--
Sihuan Pharmaceutical Holdings Group Ltd2.37bn-91.22m15.00bn2.77k--3.04--6.32-0.0098-0.00980.25720.53960.18941.493.86889,784.80-3.05-3.60-5.01-5.0566.2973.13-16.08-19.741.61-1.360.1606--2.18-7.96-301.10---20.583.60
CF PharmTech Inc683.23m31.40m15.03bn574.00478.9013.86146.4621.990.07620.07621.662.63----------------80.18--4.60--1.89--0.076--9.23---33.53------
Consun Pharmaceutical Group Ltd3.70bn1.14bn16.29bn3.07k14.563.3513.384.411.331.334.315.770.56422.3512.331,168,238.0017.6014.7124.6722.8276.6275.0431.2029.563.32--0.051740.9314.5611.4216.0562.72-9.5425.83
Zai Lab Ltd3.45bn-1.62bn17.10bn1.87k--2.82--4.96-1.52-1.523.215.370.41193.196.53---19.29-33.80-27.61-39.1261.5264.07-46.83-186.772.68--0.2108--49.5998.3823.17--32.19--
Ascletis Pharma Inc2.67m-292.52m17.61bn208.00--7.57--6,586.39-0.299-0.2990.00272.190.00110.266811.5911,577.58-12.10-8.46-12.73-8.8036.217.91-10,937.78-522.1214.53--0.0023---97.73-62.52-107.95---40.26--
Vigonvita Life Sciences Co Ltd-100.00bn-100.00bn20.11bn---------------------------------------------------94.07---1,848.73------
HUTCHMED (China) Ltd4.71bn3.65bn20.31bn1.78k5.572.115.424.324.184.185.3911.010.39667.093.862,598,691.0030.79-9.5540.72-13.7744.1539.8477.64-20.324.51--0.07---24.8025.20-62.56--15.93--
Ab&B Bio Tech Co Ltd JS366.27m-253.90m22.39bn583.00--587.93--61.12-0.6453-0.64530.93090.0968----------------67.29---69.32--0.3162-9.490.9646--397.65--39.09------
Data as of Feb 16 2026. Currency figures normalised to Zai Lab Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

21.66%Per cent of shares held by top holders
HolderShares% Held
Wellington Management Co. LLPas of 31 Dec 202548.11m4.30%
Goldman Sachs International (Invt Mgmt)as of 18 Sep 202547.96m4.28%
The Vanguard Group, Inc.as of 04 Feb 202639.45m3.52%
GF Fund Management Co., Ltd.as of 30 Jun 202522.47m2.01%
Fidelity Management & Research Co. LLCas of 29 Oct 202521.25m1.90%
Fidelity Management & Research (Hong Kong) Ltd.as of 29 Oct 202518.51m1.65%
BlackRock Fund Advisorsas of 06 Feb 202614.80m1.32%
China Universal Asset Management Co., Ltd.as of 30 Jun 202510.93m0.98%
ICBC UBS Asset Management Co. Ltd.as of 30 Jun 202510.47m0.94%
Bosera Asset Management Co., Ltd.as of 30 Jun 20258.54m0.76%
More ▼
Data from 30 Jun 2025 - 12 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.